Fixed-dose combination of lercanidipine/enalapril in the treatment of hypertension in the elderly

Papers of special note have been highlighted as: • of interest •• of considerable interest

Bibliography

• 1  Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J: Global burden of hypertension: analysis of worldwide data. Lancet365(9455),217–223 (2005).
  MedlineGoogle Scholar
• 2  Ong KL, Cheung BM, Man YB, Lau CP, Lam KS: Prevalence, awareness, treatment, and control of hypertension among United States adults 1999–2004. Hypertension49(1),69–75 (2007).
  Medline CASGoogle Scholar
• 3  Vasan RS, Larson MG, Leip EP et al.: Impact of high–normal blood pressure on the risk of cardiovascular disease. N. Engl. J. Med.345(18),1291–1297 (2001).
  Medline CASGoogle Scholar
• 4  Chobanian AV: Clinical practice. Isolated systolic hypertension in the elderly. N. Engl. J. Med.357(8),789–796 (2007).• Concise review of the pathogenesis and management of isolated systolic hypertension in the elderly.
  Medline CASGoogle Scholar
• 5  Moser M, Setaro JF: Clinical practice. Resistant or difficult-to-control hypertension. N. Engl. J. Med.355(4),385–392 (2006).
  Medline CASGoogle Scholar
• 6  Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet360(9349),1903–1913 (2002).• A milestone meta-analysis demonstrating the firm association between blood pressure elevation and cardiovascular mortality in all age groups.
  MedlineGoogle Scholar
• 7  Rothwell PM, Coull AJ, Silver LE et al.: Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). Lancet366(9499),1773–1783 (2005).
  Medline CASGoogle Scholar
• 8  Beckett NS, Peters R, Fletcher AE et al.: Treatment of hypertension in patients 80 years of age or older. N. Engl. J. Med.358(18),1887–1898 (2008).•• First randomized, prospective study to demonstrate the beneficial effects of treating hypertension in the very old.
  Medline CASGoogle Scholar
• 9  Turnbull F, Neal B, Algert C et al.: Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch. Intern. Med.165(12),1410–1419 (2005).
  MedlineGoogle Scholar
• 10  Staessen JA, Li Y, Thijs L, Wang JG: Blood pressure reduction and cardiovascular prevention: an update including the 2003–2004 secondary prevention trials. Hypertens. Res.28(5),385–407 (2005).
  MedlineGoogle Scholar
• 11  Turnbull F, Neal B, Ninomiya T et al.; Blood Pressure Lowering Treatment Trialists’ Collaboration: Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ336(7653),1121–1123 (2008).
  Medline CASGoogle Scholar
• 12  Julius S, Kjeldsen SE, Weber M et al.: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet363(9426),2022–2031 (2004).
  Medline CASGoogle Scholar
• 13  ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group; The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA288(23),2981–2997 (2002).
  MedlineGoogle Scholar
• 14  Dahlof B, Devereux RB, Kjeldsen SE et al.: Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet359(9311),995–1003 (2002).
  Medline CASGoogle Scholar
• 15  Pepine CJ, Handberg EM, Cooper-DeHoff RM et al.: A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil–Trandolapril Study (INVEST): a randomized controlled trial. JAMA290(21),2805–2816 (2003).
  Medline CASGoogle Scholar
• 16  Dahlof B, Sever PS, Poulter NR et al.: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo–Scandinavian Cardiac Outcomes Trial – Blood Pressure Lowering Arm (ASCOT – BPLA): a multicentre randomised controlled trial. Lancet366(9489),895–906 (2005).
  MedlineGoogle Scholar
• 17  Chobanian AV, Bakris GL, Black HR et al.: Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension42(6),1206–1252 (2003).
  Medline CASGoogle Scholar
• 18  Mancia G, De Backer G, Dominiczak A et al.: 2007 guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens.25(6),1105–1187 (2007).
  Medline CASGoogle Scholar
• 19  Zidek W, Dusing R, Haller H et al.: New recommendations of the German Hypertension League for the drug treatment of hypertension. Dtsch. Med. Wochenschr.128(47),2468–2469 (2003).
  Medline CASGoogle Scholar
• 20  Bangalore S, Kamalakkannan G, Parkar S, Messerli FH: Fixed-dose combinations improve medication compliance: a meta-analysis. Am. J. Med.120(8),713–719 (2007).
  MedlineGoogle Scholar
• 21  Stump CS, Hamilton MT, Sowers JR: Effect of antihypertensive agents on the development of Type 2 diabetes mellitus. Mayo. Clin. Proc.81(6),796–806 (2006).
  Medline CASGoogle Scholar
• 22  Elliott WJ, Meyer PM: Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet369(9557),201–207 (2007).
  Medline CASGoogle Scholar
• 23  Bakris G, Molitch M, Hewkin A et al.: Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care29(12),2592–2597 (2006).• Interesting study demonstrating the unfavorable metabolic effects of diuretics in patients with impaired glucose tolerance, even in the presence of renin–angiotensin system inhibitors.
  Medline CASGoogle Scholar
• 24  Lindholm LH, Carlberg B, Samuelsson O: Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet366(9496),1545–1553 (2005).
  Medline CASGoogle Scholar
• 25  Williams B, Lacy PS, Thom SM et al.: Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation113(9),1213–1225 (2006).
  Medline CASGoogle Scholar
• 26  Dart AM, Cameron JD, Gatzka CD et al.: Similar effects of treatment on central and brachial blood pressures in older hypertensive subjects in the Second Australian National Blood Pressure Trial. Hypertension49(6),1242–1247 (2007).
  Medline CASGoogle Scholar
• 27  Mancia G, Messerli F, Bakris G, Zhou Q, Champion A, Pepine CJ: Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR–Trandolapril Study. Hypertension50(2),299–305 (2007).
  Medline CASGoogle Scholar
• 28  Haller H: Effective management of hypertension with dihydropyridine calcium channel blocker-based combination therapy in patients at high cardiovascular risk. Int. J. Clin. Pract.62(5),781–790 (2008).
  Medline CASGoogle Scholar
• 29  Jamerson K, Weber MA, Bakris GL et al.: Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med.359(23),2417–2428 (2008).•• First study to directly compare fixed-dose combinations in the treatment of high-risk hypertensive patients.
  Medline CASGoogle Scholar
• 30  Todd PA, Goa KL: Enalapril. A reappraisal of its pharmacology and therapeutic use in hypertension. Drugs43(3),346–381 (1992).
  Medline CASGoogle Scholar
• 31  Cherubini A, Fabris F, Ferrari E, Cucinotta D, Antonelli Incalzi R, Senin U: Comparative effects of lercanidipine, lacidipine, and nifedipine gastrointestinal therapeutic system on blood pressure and heart rate in elderly hypertensive patients: the Elderly and Lercanidipine (ELLE) study. Arch. Gerontol. Geriatr.37(3),203–212 (2003).
  Medline CASGoogle Scholar
• 32  Poncelet P, Ribstein J, Goullard L, Bassous M, Gres CS, Clerson P: Efficacy and acceptability of lercanidipine are not age dependent in patients with essential hypertension: the AGATE study. Ann. Cardiol. Angeiol. (Paris)53(3),123–130 (2004).
  Medline CASGoogle Scholar
• 33  Barrios V, Escobar C, de la Figuera M et al.: Tolerability of high doses of lercanidipine versus high doses of other dihydropyridines in daily clinical practice: the TOLERANCE Study. Cardiovasc. Ther.26 (1),2–9 (2008).
  Medline CASGoogle Scholar
• 34  Barrios V, Escobar C, Navarro A et al.: Lercanidipine is an effective and well tolerated antihypertensive drug regardless the cardiovascular risk profile: the LAURA study. Int. J. Clin. Pract.60(11),1364–1370 (2006).
  Medline CASGoogle Scholar
• 35  Burnier M, Gasser UE: Efficacy and tolerability of lercanidipine in patients with hypertension: results of a Phase IV study in general practice. Expert Opin. Pharmacother.8(14),2215–2223 (2007).
  Medline CASGoogle Scholar
• 36  Bang LM, Chapman TM, Goa KL: Lercanidipine: a review of its efficacy in the management of hypertension. Drugs63(22),2449–2472 (2003).• Concise review of the pharmacodynamic and pharmacokinetic actions of lercanidipine.
  Medline CASGoogle Scholar
• 37  Borghi C: Lercanidipine in hypertension. Vasc. Health Risk Manag.1(3),173–182 (2005).
  Medline CASGoogle Scholar
• 38  Beckey C, Lundy A, Lutfi N: Lercanidipine in the treatment of hypertension. Ann. Pharmacother.41(3),465–473 (2007).
  Medline CASGoogle Scholar
• 39  Hair PI, Scott LJ, Perry CM: Fixed-dose combination lercanidipine/enalapril. Drugs67(1),95–106; discussion 107–108 (2007).
  Medline CASGoogle Scholar
• 40  Menne J, Haller H: Fixed-dose lercanidipine/enalapril for hypertension. Drugs Today (Barc.)44(4),261–270 (2008).
  Medline CASGoogle Scholar
• 41  Brixius K, Gross T, Tossios P et al.: Increased vascular selectivity and prolonged pharmacological efficacy of the L-type Ca²⁺ channel antagonist lercanidipine in human cardiovascular tissue. Clin. Exp. Pharmacol. Physiol.32(9),708–713 (2005).
  Medline CASGoogle Scholar
• 42  Menne J, Park JK, Agrawal R et al.: Cellular and molecular mechanisms of tissue protection by lipophilic calcium channel blockers. FASEB J.20(7),994–996 (2006).
  Medline CASGoogle Scholar
• 43  Martinez ML, Rizzi E, Castro MM et al.: Lercanidipine decreases vascular matrix metalloproteinase-2 activity and protects against vascular dysfunction in diabetic rats. Eur. J. Pharmacol.599(1–3),110–116 (2008).
  Medline CASGoogle Scholar
• 44  Rachmani R, Levi Z, Zadok BS, Ravid M: Losartan and lercanidipine attenuate low-density lipoprotein oxidation in patients with hypertension and Type 2 diabetes mellitus: a randomized, prospective crossover study. Clin. Pharmacol. Ther.72(3),302–307 (2002).
  Medline CASGoogle Scholar
• 45  Robles NR, Ocon J, Gomez CF et al.: Lercanidipine in patients with chronic renal failure: the ZAFRA study. Ren. Fail.27(1),73–80 (2005).
  Medline CASGoogle Scholar
• 46  Dalla Vestra M, Pozza G, Mosca A et al.: Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study (Diabete, Ipertensione, Albuminuria, Lercanidipina). Diabetes Nutr. Metab.17(5),259–266 (2004).
  Medline CASGoogle Scholar
• 47  Arafat T, Awad R, Hamad M et al.: Pharmacokinetics and pharmacodynamics profiles of enalapril maleate in healthy volunteers following determination of enalapril and enalaprilat by two specific enzyme immunoassays. J. Clin. Pharm. Ther.30(4),319–328 (2005).
  Medline CASGoogle Scholar
• 48  Rouini M, Hamidi M, Ghayoumi A, Ismailpour A: Relationship of serum ACE inhibition to oral dose of enalapril in normotensive volunteers. J. Clin. Pharm. Ther.27(2),121–126 (2002).
  Medline CASGoogle Scholar
• 49  Brown NJ, Vaughan DE: Angiotensin-converting enzyme inhibitors. Circulation97(14),1411–1420 (1998).
  Medline CASGoogle Scholar
• 50  Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R: Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with Type 2 diabetes mellitus. A randomized, controlled trial. Ann. Intern. Med.128(12 Pt 1),982–988 (1998).
  Medline CASGoogle Scholar
• 51  Rizzoni D, Porteri E, De Ciuceis C et al.: Effect of treatment with candesartan or enalapril on subcutaneous small artery structure in hypertensive patients with noninsulin-dependent diabetes mellitus. Hypertension45(4),659–665 (2005).
  Medline CASGoogle Scholar
• 52  Hosomi N, Mizushige K, Ohyama H et al.: Angiotensin-converting enzyme inhibition with enalapril slows progressive intima-media thickening of the common carotid artery in patients with non-insulin-dependent diabetes mellitus. Stroke32(7),1539–1545 (2001).
  Medline CASGoogle Scholar
• 53  Krysiak R, Okopien B: Pleiotropic effects of angiotensin-converting enzyme inhibitors in normotensive patients with coronary artery disease. Pharmacol. Rep.60(4),514–523 (2008).
  Medline CASGoogle Scholar
• 54  Agabiti Rosei E, Morelli P, Rizzoni D: Effects of nifedipine GITS 20 mg or enalapril 20 mg on blood pressure and inflammatory markers in patients with mild-moderate hypertension. Blood Press. Suppl.1,14–22 (2005).
  MedlineGoogle Scholar
• 55  The SOLVD Investigators: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N. Engl. J. Med.327(10),685–691 (1992).
  MedlineGoogle Scholar
• 56  Yusuf S, Pepine CJ, Garces C et al.: Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet340(8829),1173–1178 (1992).
  Medline CASGoogle Scholar
• 57  Elung-Jensen T, Heisterberg J, Sonne J, Strandgaard S, Kamper AL: Enalapril dosage in progressive chronic nephropathy: a randomised, controlled trial. Eur. J. Clin. Pharmacol.61(2),87–96 (2005).
  Medline CASGoogle Scholar
• 58  Puig JG, Calvo C, Luurila O et al.: Lercanidipine, enalapril and their combination in the treatment of elderly hypertensive patients: placebo-controlled, randomized, crossover study with four ABPM. J. Hum. Hypertens.21(12),917–924 (2007).• Enalapril and lercanidipine administered concomitantly in elderly patients exhibit a good antihypertensive action and are well tolerated.
  Medline CASGoogle Scholar
• 59  Agrawal R, Marx A, Haller H: Efficacy and safety of lercanidipine versus hydrochlorothiazide as add-on to enalapril in diabetic populations with uncontrolled hypertension. J. Hypertens.24(1),185–192 (2006).• Only study that has evaluated the efficacy and safety of the combination therapy of lercanidipine and enalapril in patients with diabetes mellitus and hypertension.
  Medline CASGoogle Scholar
• 60  Gojanovic B, Feihl F, Liaudet L, Waeber B: Concomitant calcium entry blockade and inhibition of the renin-angiotensin system: a rational and effective means for treating hypertension. J. Renin Angiotensin Aldosterone Syst.9(1),1–9 (2008).• Detailed overview focusing on the pathophysiological rationale of combining an angiotensin-converting enzyme inhibitor and a calcium-channel blocker.
  Medline CASGoogle Scholar
• 61  Cooper WO, Hernandez-Diaz S, Arbogast PG et al.: Major congenital malformations after first-trimester exposure to ACE inhibitors. N. Engl. J. Med.354(23),2443–2451 (2006).
  Medline CASGoogle Scholar